Frequent Loss of HLA-A2 Expression in Metastasizing Ovarian Carcinomas Associated with Genomic Haplotype Loss and HLA-A2-Restricted HER-2/neu-Specific Immunity
Open Access
- 15 June 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 66 (12), 6387-6394
- https://doi.org/10.1158/0008-5472.can-06-0029
Abstract
Defective expression of HLA class I molecules is common in tumor cells and may allow escape from CTL-mediated immunity. We here investigate alterations in expression of HLA class I and their underlying molecular mechanisms in ovarian cancer patients. The HLA class I and HLA-A2 expression levels on noncultured tumor cells of 12 patients diagnosed with ovarian carcinoma were investigated by flow cytometry. Molecular analyses of antigen-processing machinery (APM) components were done in metastatic cancer cells, and the HLA genotype was determined in both these and the primary tumor. HER-2/neu-specific immunity was evaluated by enzyme-linked immunospot assays. The metastatic tumor cells from all patients expressed low levels of HLA class I surface antigens. In six of nine HLA-A2+ patients, HLA-A2 expression was heterogeneous with a subpopulation of tumor cells exhibiting decreased or absent HLA-A2 expression. One patient-derived tumor cell line completely lacked HLA-A2 but exhibited constitutive expression of APM components and high HLA class I expression that was further inducible by IFN-γ treatment. Genotyping showed a haplotype loss in the metastatic tumor cells, whereas tumor tissue microdissected from the primary tumor exhibited an intact HLA gene complex. Interestingly, HLA-A2-restricted HER-2/neu-specific T-cell responses were evident among the lymphocytes of this patient. Abnormalities in HLA class I antigen expression are common features during the progression of ovarian cancer, and haplotype loss was, for the first time, described as an underlying mechanism. (Cancer Res 2006; 66(12): 6387-94)Keywords
This publication has 43 references indexed in Scilit:
- Human leucocyte antigen (HLA) A2 as a negative clinical prognostic factor in patients with advanced ovarian cancerGynecologic Oncology, 2006
- Immunoselective Pressure and Human Leukocyte Antigen Class I Antigen Machinery Defects in Microsatellite Unstable Colorectal CancersCancer Research, 2005
- Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implicationsOncogene, 2005
- Loss of heterozygosity in the HLA class I region in human pancreatic cancerTissue Antigens, 2004
- Results of clinical trials with an allogeneic melanoma tumor cell lysate vaccine: Melacine®Seminars in Cancer Biology, 2003
- HLA class I defects in malignant lesions: What have we learned?The Keio Journal of Medicine, 2003
- Mechanisms of escape from CD8+ T-cell clones specific for the HER-2/NEU proto-oncogene expressed in ovarian carcinomas: Related and unrelated to decreased MHC class 1 expressionInternational Journal of Cancer, 1997
- Cytotoxic T Cells Isolated from Ovarian Malignant Ascites Recognize a Peptide Derived from the HER-2/neu Proto-oncogeneCellular Immunology, 1993
- Partial purification and some properties of BB7.2 a cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28Human Immunology, 1981
- A monoclonal antibody that recognizes an antigenic determinant shared by HLA A2 and B17Human Immunology, 1980